60
Participants
Start Date
October 3, 2023
Primary Completion Date
February 2, 2024
Study Completion Date
February 8, 2024
influenza B/Connecticut/1/21 virus part a dose arm 1
Medium dose, expected to be approximately 10\^6 tissue culture infective dose 50% (TCID50)/mL (titer may be adjusted based on stock titer)
influenza B/Connecticut/1/21 virus part a dose arm 2
High dose, expected to be approximately 10\^7 TCID50/ mL (titer may be adjusted based on stock titer)
influenza B/Connecticut/1/21 virus part b dose 1
Extension of one of the Part A dose arms; which one is to be determined (TBD) depending on outcome of Part A, AND/OR Dose Arm 3
influenza B/Connecticut/1/21 virus part b dose 2
Addition of a 3rd dose, TBD depending on outcome of Part A
RECRUITING
QMB, London